Get the Stockscreener App
2.845
14.56%
-0.485
After Hours:
2.85
0.005
+0.18%
Cero Therapeutics Holdings Inc stock is traded at $2.845, with a volume of 505.87K.
It is down -14.56% in the last 24 hours and down -47.31% over the past month.
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
See More
Previous Close:
$3.33
Open:
$3.22
24h Volume:
505.87K
Relative Volume:
2.78
Market Cap:
$3.43M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-46.52%
1M Performance:
-47.31%
6M Performance:
-98.94%
1Y Performance:
-99.93%
1-Day Range:
$2.82
$3.27
1-Week Range:
$2.82
$5.6588
52-Week Range:
$2.82
$17,908.00
Cero Therapeutics Holdings Inc Stock (CERO) Company Profile
Name
Cero Therapeutics Holdings Inc
Sector
Industry
Phone
650-407-2376
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare CERO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CERO
Cero Therapeutics Holdings Inc
|
2.845 | 4.01M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Cero Therapeutics Holdings Inc Stock (CERO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-23-25 | Upgrade | D. Boral Capital | Hold → Buy |
Cero Therapeutics Holdings Inc Stock (CERO) Latest News
CERo Therapeutics Holdings Inc. Equity Warrant stock retracement – recovery analysisTrade Entry Report & Verified Swing Trading Watchlist - newser.com
How sustainable is CERo Therapeutics Holdings Inc. stock dividend payoutWeekly Trade Summary & Safe Entry Momentum Tips - newser.com
Using data tools to time your CERo Therapeutics Holdings Inc. exitJuly 2025 Fed Impact & Smart Investment Allocation Tips - newser.com
Will CERo Therapeutics Holdings Inc. see short term momentumEarnings Miss & Low Risk High Reward Ideas - newser.com
Can volume confirm reversal in CERo Therapeutics Holdings Inc. Equity Warrant2025 Support & Resistance & Safe Entry Trade Signal Reports - newser.com
Why CERo Therapeutics Holdings Inc. stock is seen as undervalued2025 Performance Recap & Step-by-Step Swing Trade Plans - newser.com
Can CERo Therapeutics Holdings Inc. stock deliver consistent earnings growth2025 Stock Rankings & Safe Entry Trade Reports - newser.com
Analyzing recovery setups for CERo Therapeutics Holdings Inc. investorsMarket Movers & AI Driven Stock Reports - newser.com
Sentiment analysis tools applied to CERo Therapeutics Holdings Inc. Equity WarrantTrade Entry Report & Step-by-Step Swing Trade Plans - newser.com
CERo Therapeutics Enters Securities Purchase Agreement - TipRanks
Why CERo Therapeutics Holdings Inc. stock is popular among millennialsForecast Cut & Technical Pattern Recognition Alerts - newser.com
Will CERo Therapeutics Holdings Inc. Equity Warrant stock go up soonTrade Analysis Report & Daily Growth Stock Investment Tips - newser.com
Analyzing recovery setups for CERo Therapeutics Holdings Inc. Equity Warrant investorsEarnings Beat & Reliable Price Breakout Signals - newser.com
Can CERo Therapeutics Holdings Inc. stock weather global recessionWeekly Volume Report & Weekly High Conviction Ideas - newser.com
Is CERo Therapeutics Holdings Inc. Equity Warrant stock oversold or undervaluedQuarterly Growth Report & Long-Term Capital Growth Ideas - newser.com
Using data models to predict CERo Therapeutics Holdings Inc. stock movementWeekly Gains Report & Entry Point Strategy Guides - newser.com
Sector ETF performance correlation with CERo Therapeutics Holdings Inc. Equity WarrantPortfolio Update Report & Community Trade Idea Sharing Platform - newser.com
CERo Therapeutics completes first cohort in AML clinical trial By Investing.com - Investing.com Nigeria
D. Boral Capital Maintains CERo Therapeutics Holdings (CERO) Buy Recommendation - Nasdaq
CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML - GlobeNewswire
CERO: Analyst Maintains Buy Rating with $30 Target | CERO Stock News - GuruFocus
Is CERo Therapeutics Holdings Inc. stock cheap at current valuationLong Setup & Free Growth Oriented Trading Recommendations - newser.com
Why CERo Therapeutics Holdings Inc. stock is rated strong buyQuarterly Market Summary & Reliable Breakout Forecasts - newser.com
Will CERo Therapeutics Holdings Inc. continue its uptrendWeekly Trend Report & Fast Moving Market Watchlists - newser.com
Applying Elliott Wave Theory to CERo Therapeutics Holdings Inc.Quarterly Trade Report & Expert Verified Stock Movement Alerts - newser.com
How to manage a losing position in CERo Therapeutics Holdings Inc. Equity WarrantEarnings Miss & Consistent Growth Stock Picks - newser.com
CERo Therapeutics completes first cohort in leukemia treatment trial - Investing.com India
CERo Therapeutics completes first cohort in leukemia treatment trial By Investing.com - Investing.com Nigeria
CERo Therapeutics Advances Phase 1 Trial of CER-1236 Following Dose Escalation Approval, Clarifies Business Position - Quiver Quantitative
CERo Therapeutics completes first cohort in AML clinical trial - Investing.com
CERo Therapeutics announces completion of first cohort of Phase 1 clinical trial of CER-1236 in AML - MarketScreener
Will CERo Therapeutics Holdings Inc. stock recover faster than market2025 Year in Review & Fast Gain Swing Trade Alerts - newser.com
Can CERo Therapeutics Holdings Inc. Equity Warrant hit a new high this month - newser.com
Is CERo Therapeutics Holdings Inc. Equity Warrant stock attractive for hedge funds2025 Price Targets & Precise Trade Entry Recommendations - newser.com
What does recent volatility data suggest for CERo Therapeutics Holdings Inc. Equity WarrantJuly 2025 Fed Impact & Low Drawdown Investment Ideas - newser.com
What MACD signals say about CERo Therapeutics Holdings Inc.2025 Short Interest & Fast Gaining Stock Reports - newser.com
Price momentum metrics for CERo Therapeutics Holdings Inc. Equity Warrant explainedJuly 2025 Momentum & Risk Adjusted Swing Trade Ideas - newser.com
Ranking CERo Therapeutics Holdings Inc. among high performing stocks via toolsCEO Change & Daily Stock Trend Reports - newser.com
Published on: 2025-10-10 02:27:43 - newser.com
How high can CERo Therapeutics Holdings Inc. stock go2025 Bull vs Bear & Risk Controlled Stock Pick Alerts - newser.com
Is CERo Therapeutics Holdings Inc. Equity Warrant stock a buy in volatile marketsJuly 2025 Short Interest & Weekly Breakout Opportunity Watchlist - newser.com
Smart tools for monitoring CERo Therapeutics Holdings Inc.’s price actionDay Trade & Smart Allocation Stock Reports - newser.com
Cero Therapeutics Holdings Inc Stock (CERO) Financials Data
There is no financial data for Cero Therapeutics Holdings Inc (CERO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Cero Therapeutics Holdings Inc Stock (CERO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| YK Bioventures Opportunities G | 10% Owner |
Dec 13 '24 |
Sale |
0.06 |
2,998,908 |
179,934 |
13,005,169 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 12 '24 |
Sale |
0.07 |
1,614,541 |
113,018 |
16,004,077 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 11 '24 |
Sale |
0.08 |
1,343,801 |
107,504 |
17,618,618 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 06 '24 |
Sale |
0.12 |
1,236,874 |
148,425 |
21,383,909 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 10 '24 |
Sale |
0.09 |
1,570,947 |
141,385 |
18,962,419 |
| YK Bioventures Opportunities G | 10% Owner |
Dec 09 '24 |
Sale |
0.11 |
850,543 |
93,560 |
20,533,366 |
5.15%
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):